Patrick James Villeneuve

Dr. Patrick James Villeneuve

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
PVPatrick James Villeneuve
Patrick James Villeneuve
Surgical resection of lung cancer is the preferred treatment for early-stage disease in medically fit patients. The rates of postoperative pulmonary complications (PPCs) such as pneumonia, empyema and atelectasis are as high as 10% in contemporary series. A review of the literature was performed to identify the best evidence supporting interventions to identify, prevent and treat PPCs. The use of patient risk scores, appropriate choice of antibiotic prophylaxis, intraoperative ventilatory strategies, chest physiotherapy, sputum management and non-invasive ventilatory support were specifically discussed, as was the relevant supporting data. Recommendations to guide best practice and inform future research questions are outlined.

17 December 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
HSHeather Smith
Heather Smith
HLHeidi Li
Heidi Li
OBOlivier Brandts-Longtin
Olivier Brandts-Longtin
CYChing Yeung
Ching Yeung
DMDonna Maziak
Donna Maziak
ASAndrew J E Seely
Andrew J E Seely
OBJECTIVES: A prediction model developed by Passman et al. stratifies patients’ risk of postoperative atrial fibrillation (POAF) after major non-cardiac thoracic surgery using 3 simple factors (sex, age and preoperative resting heart rate). The model has neither undergone external validation nor proven to be relevant in current thoracic surgery practice. METHODS: A retrospective single-centre analysis of all patients who underwent major non-cardiac thoracic surgery (2008–2017) with prospective documentation of incidence and severity of POAF was used for external validation of Passman’s derivation sample (published in 2005 with 856 patients). The model calibration was assessed by evaluating the incidence of POAF and patients’ risk scores (0–6). RESULTS: A total of 2054 patients were included. Among them, POAF occurred in 164 (7.9%), compared to 147 (17.2%) in Passman’s study. Differences in our sample compared to Passman’s sample included mean heart rate (75.7 vs 73.7 bpm, P < 0.001), proportion of patients with hypertension (46.1 vs 29.4%, P < 0.001), proportion of extensive lung resections, particularly pneumonectomy (6.1 vs 21%, P < 0.001) and proportion of minimally invasive surgeries (56.6% vs 0%). The model demonstrated a positive correlation between risk scores and POAF incidence (risk score 1.2% vs 6.16%). CONCLUSIONS: The POAF model demonstrated good calibration in our population, despite a lower overall incidence of POAF compared to the derivation study. POAF rates were higher among patients with a higher risk score and undergoing procedures with greater intrathoracic dissection. This tool may be useful in identifying patients who are at risk of POAF when undergoing major thoracic surgery and may, therefore, benefit from targeted prophylactic therapy.

24 November 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
CTCalvin Thompson
Calvin Thompson
AMAmanda M S Mattice
Amanda M S Mattice
YLYaseen Al Lawati
Yaseen Al Lawati
NSNazgol Seyednejad
Nazgol Seyednejad
ALAlex Lee
Alex Lee
ASAndrew Seely
Andrew Seely
Data regarding enhanced recovery after thoracic surgery (ERATS) are sparse and inconsistent. This study aims to evaluate the effects of implementing an enhanced ERATS programme on postoperative outcomes, patient experience and quality of life (QOL). We conducted a prospective, longitudinal study evaluating 9 months before (pre-ERATS) and 9 months after (post-ERATS) a 3-month implementation of an ERATS programme in a single academic tertiary care centre. All patients undergoing major thoracic surgeries were included. The primary outcomes included length of stay (LOS), adverse events (AEs), 6-min walk test scores at 4 weeks, 30-day emergency room visits (without admission) and 30-day readmissions. The process-of-care outcomes included time to ‘out-of-bed’, independent ambulation, successful fluid intake, last chest tube removal and removal of urinary catheter. Perioperative anaesthesia-related outcomes were examined as well as patient experience and QOL scores. The pre-ERATS group (n = 352 patients) and post-ERATS group (n = 352) demonstrated no differences in demographics. Post-ERATS patients had improved LOS (4.7 vs 6.2 days, P < 0.02), 6-min walk test scores (402 vs 371 m, P < 0.05) and 30-day emergency room visits (13.7% vs 21.6%, P = 0.03) with no differences in AEs and 30-day readmissions. Patients experienced shorter mean time to ‘out-of-bed’, independent ambulation, successful fluid intake, last chest tube removal and urinary catheter removal. There were no differences in postoperative analgesia administration, patient satisfaction and QOL scores. ERATS implementation was associated with improved LOS, expedited feeding, ambulation and chest tube removal, without increasing AEs or readmissions, while maintaining a high level of patient satisfaction and QOL.

6 November 2023 in Surgeries
Verified
Journal Article
Open access
PDF file
KAKatherine Aw
Katherine Aw
ARAziza Al Rawahi
Aziza Al Rawahi
RLRebecca Lau
Rebecca Lau
SASami Aftab Abdul
Sami Aftab Abdul
CACaitlin Anstee
Caitlin Anstee
DMDonna Elizabeth Maziak
Donna Elizabeth Maziak
Background: In this study, we investigate indocyanine green (ICG) dye visualization of the thoracic duct (TD) and conduit perfusion during esophagectomy to reduce anastomotic leak (AL) and chylothorax adverse events (AEs). Methods: Retrospective data of adult patients who underwent esophagectomy for esophageal carcinoma between July 2019 and 2022 were included (n = 105). ICG was delivered intravenously (2 mL, 2.5 mg/mL) to assess conduit perfusion into the small bowel mesentery, inguinal lymph nodes, or foot web spaces for TD visualization using fluorescence imaging. Incidence of TD injury, chylothorax, AL, and AEs were collected. Results: A total of 23 patients received ICG (ICG for TD and perfusion (n = 12) and perfusion only (n = 11)), while 82 patients were controls. TD was visualized in 6 of 12 patients who received ICG for TD. No intraoperative TD injuries or postoperative chylothoraces occurred in these patients. Non-ICG patients had 1 (1.22%) intraoperative TD injury and 10 (12.2%) postoperative chylothoraces (grade I–IIIb). While 10 non-ICG patients (12.2%) developed AL (grade I–IVb), only 2 (8.7%) ICG patients developed AL (grade IIIa). Conclusions: This study demonstrates the utility of ICG fluorescence in intraoperative TD and conduit perfusion assessment for limiting AEs. Standard incorporation of ICG in esophagectomy may help surgeons improve the quality of care in this patient population.

9 February 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
ALAlex Lee
Alex Lee
NSNazgol Seyednejad
Nazgol Seyednejad
YLYaseen Al Lawati
Yaseen Al Lawati
AMAmanda Mattice
Amanda Mattice
CACaitlin Anstee
Caitlin Anstee
ASAndrew Seely
Andrew Seely
Alex Lee, B.Sc., Nazgol Seyednejad, M.D., Yaseen Al Lawati, M.D., Amanda Mattice, B.Sc., Caitlin Anstee, B.A., Mark Legacy, B.Sc., Sebastien Gilbert, M.D., Donna E. Maziak, M.D.C.M., M.Sc., Ramanadhan S. Sundaresan, M.D., Patrick J. Villeneuve, M.D.C.M., Ph.D., Calvin Thompson, M.D., Andrew J. E. Seely, M.D., Ph.D.. J Chest Surg 2022;55:118-25. https://doi.org/10.5090/jcs.21.139

8 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
PCParneet K. Cheema
Parneet K. Cheema
PWPaul Wheatley-Price
Paul Wheatley-Price
MCMatthew J. Cecchini
Matthew J. Cecchini
PEPeter Ellis
Peter Ellis
ALAlexander Louie
Alexander Louie
NLNatasha Leighl
Natasha Leighl
Therapeutic strategies for early-stage non-small cell lung cancer (NSCLC) are advancing, with immune checkpoint inhibitors (ICIs) and targeted therapies making their way into neoadjuvant and adjuvant settings. With recent advances, there was a need for multidisciplinary lung cancer healthcare providers from across Ontario to convene and review recent data from practical and implementation standpoints. The focus was on the following questions: (1) To what extent do patient (e.g., history of smoking) and disease (e.g., histology, tumor burden, nodal involvement) characteristics influence treatment approaches? (2) What are the surgical considerations in early-stage NSCLC? (3) What is the role of radiation therapy in the context of recent evidence? (4) What is the impact of biomarker testing on treatment planning? Ongoing challenges, treatment gaps, outstanding questions, and controversies with the data were assessed through a pre-meeting survey, interactive cases, and polling questions. By reviewing practice patterns across Ontario cancer centers in the context of evolving clinical data, Health Canada indications, and provincial (Cancer Care Ontario [CCO]) funding approvals, physicians treating lung cancer voiced their opinions on how new approaches should be integrated into provincial treatment algorithms. This report summarizes the forum outcomes, including pre-meeting survey and polling question results, as well as agreements on treatment approaches based on specific patient scenarios.